Brinzolamide/timolol fixed combination for open-angle glaucoma and ocular hypertension

Abstract

The brinzolamide/timolol fixed combination contains brinzolamide 1% and timolol maleate 0.5% in ophthalmic suspension produced for twice-daily application to reduce elevated intraocular pressure in open-angle glaucoma and ocular hypertension. This fixed combination was recently approved by the European Medicines Agency, in December 2008. The brimzolamide/timolol fixed combination provides an approximately 30–33% intraocular pressure reduction from the untreated baseline of 25–27 mmHg, thus is more potent than any of its ingredients alone and is similarly effective but better tolerated than the dorzolamide/timolol fixed combination, which consists of molecules from the same drug classes. The fixed combination of brinzolamide and timolol can be used as a separate therapy, but due to the additivity of its ingredients to drugs belonging to other classes, it may also be administered in combination with other intraocular pressure-lowering molecules, most importantly topical prostaglandin analogues.